SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001640334-23-002021
Filing Date
2023-11-06
Accepted
2023-11-06 09:59:54
Documents
12
Period of Report
2023-11-03

Document Format Files

Seq Description Document Type Size
1 FORM 6-K nymox_6k.htm 6-K 14206
2 EX-99.1 nymox_ex991.htm EX-99.1 20297
3 EX-99.2 nymox_ex992.htm EX-99.2 22995
4 EX-99.3 nymox_ex993.htm EX-99.3 23147
5 EX-99.4 nymox_ex994.htm EX-99.4 12625
6 EX-99.5 nymox_ex995.htm EX-99.5 5502
7 nymox_ex993img1.jpg GRAPHIC 4621
8 nymox_ex991img2.jpg GRAPHIC 4624
9 nymox_ex995img1.jpg GRAPHIC 4619
10 nymox_ex992img2.jpg GRAPHIC 4583
11 nymox_ex992img1.jpg GRAPHIC 4834
12 nymox_ex991img1.jpg GRAPHIC 4839
  Complete submission text file 0001640334-23-002021.txt   139333
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-12033 | Film No.: 231378802
SIC: 2835 In Vitro & In Vivo Diagnostic Substances